Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in Sweden and internationally. It primarily focuses on breast cancer. The company develops DiviTum TKa, a biomarker assay that measures thymidine kinase activity, which reflects tumor cell proliferation. It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.
Stock data | 2023 | Change |
---|---|---|
Price | $0.24511846575449917 | N/A |
Market Cap | $8.45M | N/A |
Shares Outstanding | 34.46M | 19.84% |
Employees | 37.00 | N/A |
Shareholder Equity | 138.64M | 11.72% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -0.08 | N/A |
P/S Ratio | 25.46 | N/A |
P/B Ratio | 0.06 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.0781 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $331.79K | N/A |
Earnings | -$10.83M | N/A |
EPS | -3.20 | N/A |
Earnings Yield | -13.07 | N/A |
Gross Margin | 1.36 | N/A |
Operating Margin | -32.78 | N/A |
Net income margin | -32.65 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $16.89M | N/A |
Total Debt | $1.02M | N/A |
Cash on Hand | $11.21M | N/A |
Debt to Equity | 0.0238 | 9.36% |
Cash to Debt | $10.94 | 41.81% |
Current Ratio | $5.08 | -13.93% |